Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Assets: 2020-2025

Historic Assets for Caribou Biosciences (CRBU) over the last 5 years, with Sep 2025 value amounting to $195.0 million.

  • Caribou Biosciences' Assets fell 43.37% to $195.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $195.0 million, marking a year-over-year decrease of 43.37%. This contributed to the annual value of $313.3 million for FY2024, which is 27.51% down from last year.
  • As of Q3 2025, Caribou Biosciences' Assets stood at $195.0 million, which was down 11.73% from $220.9 million recorded in Q2 2025.
  • In the past 5 years, Caribou Biosciences' Assets registered a high of $462.0 million during Q3 2021, and its lowest value of $158.4 million during Q2 2021.
  • Its 3-year average for Assets is $337.6 million, with a median of $347.5 million in 2023.
  • In the last 5 years, Caribou Biosciences' Assets skyrocketed by 1,127.20% in 2021 and then plummeted by 43.37% in 2025.
  • Caribou Biosciences' Assets (Quarterly) stood at $442.4 million in 2021, then decreased by 15.51% to $373.8 million in 2022, then increased by 15.64% to $432.2 million in 2023, then decreased by 27.51% to $313.3 million in 2024, then crashed by 43.37% to $195.0 million in 2025.
  • Its Assets was $195.0 million in Q3 2025, compared to $220.9 million in Q2 2025 and $273.7 million in Q1 2025.